Location

Rua Câmara Pestana, n.º 6, piso 1 | 1150-082 Lisboa

Guadalupe Cabral

Researcher
Principal Investigator

After graduating in Biology in 1999 from the Faculdade de Ciências, Universidade de Lisboa, MGC pursued a PhD at Instituto Superior Técnico, where she investigated mechanisms of stress resistance. In 2007, she joined NOVA Medical School as a postdoctoral researcher in Immunology and has been an Invited Assistant Professor at the same institution since 2012. More recently, she was appointed Principal Investigator, establishing the Translational Tumor Immunology group within NOVA Medical School.
Her research focuses on understanding the immune response in cancer, aiming to identify predictive and prognostic biomarkers and to develop new immune-based therapeutic strategies, particularly for breast cancer. Through a combination of molecular, cellular, and translational approaches, her group seeks to connect fundamental immunology with clinical applications, contributing to the development of more effective cancer immunotherapies.

MGC has authored or co-authored 37 scientific articles and 3 book chapters, and has recently submitted a patent highlighting the translational potential of her work. Her research has been recognized through several prizes and awards in the fields of cancer biology and immunology.

In addition to her research activities, MGC is actively involved in academic teaching and mentoring, having supervised and co-supervised several PhD and MSc students. She continues to foster strong collaborations with clinicians to advance translational studies aimed at improving breast cancer management.

  • Correia BF, Grosa D, Salvador R; Brites I, Martins T, Braga S, Sousa CX, Vitorino M, Jacinto A, Cabral MG. Neutrophils matter: New clinical insights on their role in metastatic Breast Cancer progression. bioRxiv. 2025. doi.org/10.1101/2025.04.11.648384
  • Salvador R, Correia BF; Grosa D; Martins T; Soares Baal SC, Saraiva DP, Cristovão-Ferreira S, Pereira IL, Rebelo de Almeida C, Fior R, Jacinto A, Mathias C, Braga S, Cabral MG. HLA-DR expression in Cytotoxic T Lymphocytes: a key to boost the therapeutic potential of T cell- based strategies for Breast Cancer. Frontiers in Immunology. 2025 Sep 19;16:1653970. doi.org/10.3389/fimmu.2025.1653970.
  • Tomás A, Roquel L, Francisco I, Silva AL, Nunes H, Gouveia E, Carvalho E, Farricha V, Moura C, Rosa JC, Garrido PM, Albuquerque C, Pereira P, Cabral MG, et al. A novel patient-derived cutaneous melanoma cell line reveals key features of metastatic melanoma. Frontiers in Oncology. 2025 Jul 18;15:1531013. doi: 10.3389/fonc.2025.1531013.
  • Domingues NS, Gaifen J, Matthisen R, Saraiva DP*, Bento L, Marques A, Sampaio J, Hlose C, Surma M, Almeida, MS, Mendes G, Gonçalves PA, Ferreira J, Melo RG, Pedro LM, Simmons K, Pinho e Melo TMVPD, MG Cabral, et al. Cholesteryl hemiazelate idenditied in cardivascular disease patients causes in vitro and in vivo inflammation. J Lipid Res. 2023 64(9). doi.org/10.1016/j.jlr.2023.100419
  • Coelho S, Cabral MG, Salvador R, Andrade C, Martins A, Correia BF, Freitas P, Maria Cruzado J, Jacinto A. Urinary immune cell phenotype of severe AKI in critically ill patients. International Urology and Nephrology. 2022 Aug; 54(8):2047-2055. DOI: 10.1007/s11255-021-03088-y
  • Saraiva DP, Correia BF, Salvador R, De Sousa N, Jacinto A, Braga S, Cabral MG. Circulating Low Density Neutrophils of Breast Cancer Patients are Associated with their Worse Prognosis due to the Impairment of T cell Responses. Oncotarget. 2021 Nov 23;12(24): 2388-2403.DOI: 10.18632/oncotarget.28135.
  • Silva G, Sales-Dias J, Casal D, Alves S, Domenici G, Barreto C, Matos C, Lemos AR, Matias AT, Kucheryava K, Ferreira A, Moita MR, Braga S, Brito C, Cabral MG, Casalou C, Barral DC, Sousa PMF, Videira PA, Bandeiras TM, Barbas A.Development of Dl1.72, a Novel Anti-DLL1 Antibody with Anti-Tumor Efficacy against Estrogen Receptor-Positive Breast Cancer. Cancers 2021.13(16):4074. DOI: 10.3390/cancers13164074
  • Saraiva DP, Azeredo-Lopes S, Antunes A, Salvador R, Borralho P, Assis B, Pereira, IL, Seabra Z, Negreiros I, Jacinto A, Braga S, Cabral MG. Expression of HLA-DR in Cytotoxic T Lymphocytes: A Validated Predictive Biomarker and a Potential Therapeutic Strategy in Breast Cancer. Cancers. 2021 Jul 30;13(15):3841. doi: 10.3390/cancers13153841.
  • Saraiva DP, Matias AT, Braga S, Jacinto A, Cabral MG. Establishment of a 3D Co-culture With MDA-MB-231 Breast Cancer Cell Line and Patient-Derived Immune Cells for Application in the Development of Immunotherapies. Frontiers in Oncology. 2020 Aug 27;10:1543. doi: 10.3389/fonc.2020.01543
  • Saraiva DP, Jacinto A, Borralho P, Braga S, Cabral MG. HLA-DR expression in cytotoxic T Lymphocytes predicts Breast Cancer patients’ response to neoadjuvant chemotherapy. Frontiers in Immunology. 2018 Nov 13;9:2605. doi: 10.3389/fimmu.2018.02605.
  • 2025: Research Grant within MPS NOVA Twinning
  • 2024: Research Grant from Liga Portuguesa Contra o Cancro
  • 2024: Research Grant from Gilead Génese Program
  • 2023: CaixaImpulse Innovation Grant from ‘la Caixa’ foundation
  • 2023: Best Paper Award by Portuguese Nephrology Society
  • 2021: iNOVA4Health Grant (UIBD/04462/2020) – internal competitive call
  • 2020: Scicare-Novartis Health Science accelerator program
  • 2019: Pfizer/Sociedade das Ciências Médicas - prize on the category of Clinical Research
  • 2019: Liga Portuguesa Contra o Cancro/Terry Fox Research Grant
  • 2018: Tagus Tank Consortium – Projects in Medicine Prize